- Chief Financial Officer Steve Chaussy retires following
12 years of service
- Steve Buhaly joins BioSig as CFO
- Buhaly brings 15 years of public company
CFO experience, including 9 years of leadership with RF chip
technology giant Qorvo
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), an advanced digital signal processing technology
company delivering accuracy and precision to intracardiac signal
visualization with its proprietary PURE EP™ System, today announced
the retirement of chief financial officer Steve Chaussy following a
distinguished career with the Company, and has named Steve Buhaly
as his successor. Mr. Buhaly brings over 15 years of CFO
experience at three public U.S. companies to his new role with
BioSig.
“Steve Chaussy joined BioSig in 2011, making him one of our most
veteran executives,” said BioSig Chairman and CEO Kenneth L.
Londoner. “Steve successfully organized the financial foundation of
our Company, supporting major corporate milestones achieved by
BioSig over the past decade. We are grateful for his commitment
throughout many years of service and wish him all the best in his
retirement.”
Mr. Chaussy’s successor Steve Buhaly is a long-tenured finance
and technology executive who joined Qorvo (formerly TriQuint
Semiconductor) as CFO in 2007, near the time when Apple began
utilizing TriQuint chips in the iPhone. TriQuint became Qorvo in
2015 in a $4 billion combination with RF Micro Devices. During
Mr. Buhaly’s tenure, Qorvo grew into an $11 billion market
capitalization company and a world leader in innovative and
high-performance radiofrequency (RF) solutions.
Commenting on the CFO transition, Londoner continued, “This is
an especially opportune time in our Company’s evolution to welcome
Steve Buhaly to our executive team,” Mr. Londoner continued. “His
impressive pedigree includes not only 15 years of public company
CFO experience, but also deep credentials in software innovation.”.
As we continue executing our full commercial rollout of the PURE
EP™ System and scale our marketing and sales nationally, I have no
doubt that Steve’s decades-long pattern of success in financial and
operating leadership, corporate expansion, and value creation will
serve our company and our shareholders well.”
Throughout his career, Mr. Buhaly has developed a strong
cross-functional background in corporate finance, accounting, tax,
IT, law, and investor relations. He co-led strategic transactions
resulting in over $2 billion in M&A transactions and has helped
companies raise $1 billion in the debt markets. He has been
publicly recognized for his leadership during TriQuint's massive
growth trajectory.
Prior to TriQuint, Mr. Buhaly was CFO of Longview Fibre where he
played a key role in executing the $2.3 billion sale of the
company. Earlier he held both chief operating officer and chief
financial officer roles with electronic display company Planar
Systems.
Since 2018, Mr. Buhaly has served as an advisor to multiple
early-stage and small businesses and currently consults for cancer
treatment innovator UbiVac. He has invested in nine private
companies as an angel investor.
Steve Buhaly commented, “I am impressed by the integrity of
BioSig’s leadership and its game-changing technology. I believe
BioSig has the right commercial strategies in action by a proven
sales and marketing team to drive meaningful traction and growth
this year and beyond. It’s an exciting time to join BioSig and help
maximize the new opportunities ahead.”
Steve BuhalyChief Financial OfficerBioSig Technologies, Inc.
(Nasdaq: BSGM)
About BioSig Technologies
BioSig Technologies is an advanced digital signal
processing technology company bringing never-before-seen insights
to the treatment of cardiovascular arrhythmias. Through
collaboration with physicians, experts, and healthcare leaders
across the field of electrophysiology (EP), BioSig is committed to
addressing healthcare’s biggest priorities — saving time, saving
costs, and saving lives.
The Company’s first product, the PURE EP™ System, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform insight-based,
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial launch
and an integral part of well-respected healthcare systems, such as
Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic,
and Kansas City Heart Rhythm Institute. In a blinded clinical
study recently published in the Journal of Cardiovascular
Electrophysiology, electrophysiologists rated PURE EP™ as
equivalent or superior to conventional systems for 93.6% of signal
samples, with 75.2% earning a superior rating.
The global EP market is projected to reach $16B in 2028 with an
11.2% growth rate.1
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) overall market conditions, (ii)
the geographic, social and economic impact of COVID-19 on our
ability to conduct our business and raise capital in the future
when needed, (iii) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (iv) difficulties in obtaining
financing on commercially reasonable terms; (v) changes in the size
and nature of our competition; (vi) loss of one or more key
executives or scientists; and (vii) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Global Market Insights Inc. March 08, 2022.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024